Ignite Creation Date:
2025-12-24 @ 9:18 PM
Ignite Modification Date:
2026-02-25 @ 8:11 PM
Study NCT ID:
NCT02535104
Status:
COMPLETED
Last Update Posted:
2018-06-06
First Post:
2015-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003218', 'term': 'Condylomata Acuminata'}, {'id': 'D030361', 'term': 'Papillomavirus Infections'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}], 'ancestors': [{'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D004266', 'term': 'DNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D014860', 'term': 'Warts'}, {'id': 'D017193', 'term': 'Skin Diseases, Viral'}, {'id': 'D014412', 'term': 'Tumor Virus Infections'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D012874', 'term': 'Skin Diseases, Infectious'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C058703', 'term': 'ranpirnase'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 70}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-03', 'completionDateStruct': {'date': '2016-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-06-04', 'studyFirstSubmitDate': '2015-08-22', 'studyFirstSubmitQcDate': '2015-08-25', 'lastUpdatePostDateStruct': {'date': '2018-06-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2015-08-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2016-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Size of lesions', 'timeFrame': 'Up to 60 days', 'description': 'The primary endpoint is the percentage change from baseline in total area of lesions at Week 8'}], 'secondaryOutcomes': [{'measure': 'Number of lesions', 'timeFrame': 'Up to 60 days', 'description': 'Number of lesions present at Week 8'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Condylomata Acuminata', 'Papillomavirus Infections', 'Sexually Transmitted Diseases']}, 'descriptionModule': {'briefSummary': 'Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in subjects with genital warts.', 'detailedDescription': 'The study consists of the evaluation of 4 weeks exposure to the study product; designed as randomized, double blinded, against vehicle to study the effects of 1 mg/ml concentration of ranpirnase on anogenital warts.\n\nThe dermal reaction are scored on a scale that describes the amount of erythema, edema, and other features indicative of irritation.\n\nThe clinical response are be scored on the basis of the percentage of the reduction of the lesions in size and number.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosis of external genital / perianal warts with at least 2 warts and no more than 30 lesions\n* Accept to follow study instructions / signature of IC\n* Abstain from sexual intercourse for 6 hours after applying the study product during the time of the study.\n\nExclusion Criteria:\n\n* Any topical and/or destructive treatments for external genital warts within 4 weeks (within 12 months for imiquimod and within 12 weeks for sinecatechins) prior to enrollment (i.e., the randomization visit)\n* Non pregnant. For women in reproductive age it would be required pregnancy test, and the use of double barrier contraceptives.\n* Any of the following conditions:\n* Known allergy to the study product\n* Internal (rectal, urethral) warts that required or were undergoing treatment;\n* A dermatological disease (e.g., psoriasis) or skin condition in the area, which may interfere with the evaluation.\n* Imiquimod 5% cream (Aldara®)\n* Any marketed or investigational HPV vaccines\n* Sinecatechins (Veregen)\n* Interferon or interferon inducers\n* Cytotoxic drugs\n* Immunomodulators or immunosuppressives\n* Oral or parenteral corticosteroids (inhaled/intranasal steroids are permitted)\n* Oral antiviral drugs (with the exception of HAART, oral acyclovir and acyclovir related drugs) for suppressive or acute therapy herpes; or oseltamivir for prophylaxis or for influenza)\n* Topical antiviral drugs (including topical acyclovir and acyclovir related drugs) in the areas under treatment\n* Podophyllotoxin/Podofilox in the treatment areas\n* Any topical prescription medications in the treatment areas\n* Dermatologic procedures or surgery in the treatment areas'}, 'identificationModule': {'nctId': 'NCT02535104', 'briefTitle': 'Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Tamir Biotechnology, Inc.'}, 'officialTitle': 'Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV', 'orgStudyIdInfo': {'id': 'TAMIR1501HPV'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment group', 'description': '1 mg/ml solution of ranpirnase applied twice daily', 'interventionNames': ['Drug: Ranpirnase']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Control', 'description': 'Vehicle - innert gel', 'interventionNames': ['Drug: Vehicle']}], 'interventions': [{'name': 'Ranpirnase', 'type': 'DRUG', 'otherNames': ['Onconase'], 'description': 'Topical application by subject', 'armGroupLabels': ['Treatment group']}, {'name': 'Vehicle', 'type': 'DRUG', 'otherNames': ['Placebo'], 'description': 'Vehicle control', 'armGroupLabels': ['Control']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Cochabamba', 'country': 'Bolivia', 'facility': 'IDH', 'geoPoint': {'lat': -17.38195, 'lon': -66.15995}}], 'overallOfficials': [{'name': 'Edgar Valdez, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'Director - Research site'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Tamir Biotechnology, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}